Faron Pharmaceuticals: Positive BEXMAB Study Update - Redeye

Redeye leaves a note following Faron’s recent study update from the phase I/II BEXMAB study with its lead candidate, bexmarilimab. We are encouraged by the continued positive progress and the candidate’s favorable response to treatment in relapsed/refractory AML and MDS.

Länk till analysen i sin helhet: https://www.redeye.se/research/923704/faron-pharmaceuticals-positive-bexmab-study-update?utm_source=finwire&utm_medium=RSS